Menopausal Vasomotor Symptoms
Transdermal Estrogen/Progestin Combinations
For menopausal vasomotor symptoms. Women with an intact uterus who take a systemic estrogen should also take a progestogen to reduce the risk of endometrial hyperplasia and adenocarcinoma. Progestin should not be used in women who have had uterus removed. Transdermal formulations are as effective as oral estrogens in reducing vasomotor symptoms and may be safer.
Climara Pro – Estradiol/levonorgestrel
Estradiol 0.045 mg + levonorgestrel 0.015 mg; per day; transdermal system.
Once per week.
CombiPatch – Estradiol/norethindrone
Estradiol 0.05 mg + norethindrone acetate 0.14 mg; per day; transdermal system.
Estradiol 0.05 mg + norethindrone acetate 0.25 mg; per day; transdermal system.
Twice per week.
Climara Pro and CombiPatch are in table below. Note that Climara Pro is once a week.
Climara Pro – Estradiol/levonorgestrel
Estradiol 0.045 mg + levonorgestrel 0.015 mg; per day; transdermal system.
Once per week.
CombiPatch – Estradiol/norethindrone
Estradiol 0.05 mg + norethindrone acetate 0.14 mg; per day; transdermal system.
Estradiol 0.05 mg + norethindrone acetate 0.25 mg; per day; transdermal system.
Twice per week.
Climara Pro and CombiPatch are in table below. Note that Climara Pro is once a week.
Oral Contraceptives (OCPs)
Estrogen-containing OCPs contraindicated in migraine with aura.
Xulane Birth Control Patch (transdermal system)
norelgestromin and ethinyl estradiol patch (Mylan Pharmaceuticals Inc.)
Transdermal system: 150 mcg/day norelgestromin and 35 mcg/day ethinyl estradiol
Xulane uses a 28-day (4-week) cycle. Apply a new patch to the upper outer arm, abdomen, buttock or back each week for 3 weeks (21 total days). Week 4 is patch-free. Apply each new patch on the same day of the week. Wear only one patch at a time.
Transdermal system: 150 mcg/day norelgestromin and 35 mcg/day ethinyl estradiol
Xulane uses a 28-day (4-week) cycle. Apply a new patch to the upper outer arm, abdomen, buttock or back each week for 3 weeks (21 total days). Week 4 is patch-free. Apply each new patch on the same day of the week. Wear only one patch at a time.
Mean Serum Concentration-Time Profiles of EE Following Once-Daily Administration of an Oral Contraceptive for Two Cycles or Application of Norelgestromin and Ethinyl Estradiol Trans dermal System for Two Cycles to the Buttock in Healthy Female Volunteers . [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] 168 hours = 7 days
Stroke Risk
- Risk of ischemic stroke in women with migraine is about 2 times higher than that of women without migraine, driven
largely by increased risk in the subgroup of women who have migraine with aura. - An association between migraine and an approximately 1.5 times increased risk of hemorrhagic stroke has also been shown.
- Greatest increase in stroke risk is seen in women with migraine in their reproductive years, who are under the age of 45, and who otherwise have few stroke risk factors. The elevation in risk of stroke is amplified by other risk factors, particularly smoking.
- Combined hormonal contraceptives with low estrogen probably have reduced stroke risk (low estrogen OCPs: 20-25 µg ethinyl estradiol; average 35 µg; some as low as 10 µg)
- Absolute risk of stroke in reproductive-aged women is low (3.56 per 100,000 women of reproductive age per year)
Relative increased ischemic stroke risk about 3-fold
- 20 µg EE 1.6 (not clear that risk is increased)
- 30-49 µg EE 2.0 (no clear that risk is increased
- >49 µg EE 2.4 (clear increased stroke risk)
One study differentiated risk by presence or absence of migraine aura and found an increased risk in the migraine with aura population (OR 6.1 in migraine with aura vs 1.8 migraine without aura group).
Progestin-only Pill (POP) [Slynd]
Each pack includes 24 tablets containing 4 mg of drospirenone and 4 inert tablets
- Progestin-only pill (POP)
- High drospirenone, should be more effective than older progestin-only contraceptives
- Appropriate when the use of combination methods should be avoided due to elevated cardiovascular risks, including smokers age 35 and older and women with hypertension, migraines with aura, multiple cardiovascular risk factors, or a history of thrombosis.